FDA’s Pharmaceutical Inspectorate Robert Coleman National Expert Drug Investigator Food and Drug Administration.

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
Knowledge Dietary Managers Association 1 DMA Certification Exam Blueprint and Curriculum Development.
Amy Peloquin Director of Certification ~
MODULE B - PROCESS B1. ASME Organizational Structure B2. Standards Development: Staff and Volunteer Roles and Responsibilities B3. Conformity Assessment:
ESEA: Developing the Paraprofessional Portfolio Prepared by Carolyn Ellis Logan, Consultant Professional Development/Human Rights Department Michigan Education.
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
Independent Educational Evaluations Developed by Contra Costa SELPA As Recommended for LEA Board Policy
Oncologic Drugs Advisory Committee September 6, 2006 ODAC and the FDA Arms-Length or Arm-In-Arm? Abigail Alliance for Better Access to Developmental Drugs.
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
MFRPS Lesson Learned North Carolina
An Overview. HVAC Excellence was founded as a not for profit organization in 1994 to improve the technical workforce of the HVACR industry through quality.
What’s New in the FDA’s Pharmaceutical Inspectorate and Risk Based Systems Inspection Rick Perlman Chair Food, Drug, and Cosmetic Division ASQ.
SFO ® Certification Program Copyright 2015 ASBO International.
IS Audit Function Knowledge
External Quality Assessments
CBAP and BABOK Presented to the Albany Capital District Chapter of the IIBA February 3, 2009.
SAFA- IFAC Regional SMP Forum
a judgment of what constitutes good or bad Audit a systematic and critical examination to examine or verify.
Proposed Rules to Help Ensure the Safety of Imported Food 1.
1 FDIC Corporate University Aligning Learning With Corporate Objectives March 2006.
FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.
Planning an Internal Audit JM García Merced. Brainstorm.
Internal Auditing and Outsourcing
McCann Associates Presented by: Michael Childs, Barbara Dyer, Ira Taylor, Bruce Nugyen Chad Warner & Joe Koury, McCann Associates.
E-VALUE Evaluating: Vision Ability Leadership Uniformity Excellence Training and Evaluation Guide Miami-Dade County Public Schools Office of Human Capital.
Shirley Rowe March 27,  Who – developed the certification?  Why should you become certified?  Need for Career Development Facilitators (CDF)
Consultant Pharmacists
“Fit For Use” Jim Melvin Assistant Director of Regulatory Programs North Carolina Department of Agriculture and Consumer Services 3/12/14 8:00 A.M.
PREVENTION CERTIFICATION: WHAT IS THE BIG DEAL? Pam Rush, CSPP Axis I Center of Barnwell, SC IC&RC Products Chair.
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
Pennsylvania Training and Technical Assistance Network Update on Requirements for Paraprofessionals and the PA Credential of Competency A Webinar for Administrators,
Co-op at PCC Sylvania Co-op Task Force Findings and Recommendations.
The Campaign for McMaster University Environmental & Occupational Health Support Services and Central Joint Health and Safety Committee Developed from.
North London Branch 26th June 2002 ISEB Qualifications Mark Lovell Deputy Director (Examinations) The British Computer Society.
RED RIVER COLLEGE PLAR/RPL IN ACTION! Recognizing Prior Learning.
Fourth Annual Medical Research Summit Concurrent Session 4.05 – Managing CROs and SMOs from a Compliance Perspective Michael SwiatochaAprill 23, 2004.
Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.
Software Quality Assurance Lecture #2 By: Faraz Ahmed.
FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.
Comprehensive Educator Effectiveness: New Guidance and Models Presentation for the Special Education Advisory Committee Virginia Department of Education.
1 Kingsley Karunaratne, Department of Accounting, University of Sri Jayewardenepura, Colombo - Sri Lanka Practice Management.
1 Thank you for visiting our site and welcome to the “Introduction to ISO 22000” Presentation that you requested. For more information.
Federal Aviation Administration Presented to: By: Date: Oversight Throughout the Supply Chain: Is It Adequate? DOT OIG Audit: Assessment of FAA's Risk-Based.
ACADEMIC PERFORMANCE AUDIT ON AREA 1, 2 AND 3 Prepared By: Nor Aizar Abu Bakar Quality Academic Assurance Department.
April 8, Agenda Charge of the Group SACS/QEP Update/Overview 5 th Year Interim Report Assigned Areas Next Steps.
CCMEP A Certification Program for CME Professionals Serving the Public - Advancing the Profession.
Microsoft Office User Specialist Program Presentation to MPUG – June 20, 2000 Nivo International: Brent Mason, Director of Sales Oyvind Ragnhildstveit,
External Peer Review of the FDA Office of Regulatory Affairs Pesticide Program FDA Science Board Advisory Committee Meeting March 31, 2006.
Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
Career Development Professional Recognition with the Society of Biology HEaTED – Regional Network Event 23rd April 2013 Debbie Brunt Society of Biology.
United States Public Health Service -National Clinical Pharmacy Specialist (NCPS) Presentation prepared Presentation prepared by: CDR Anne Marie.
CBER Common Problems on Source Plasma Inspections Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.
Title Page Quality Mo Samimi, Ph.D. CMQ/OE Presented at the ASQ Biomedical Division Northern California Discussion Group. May 2011.
FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.
Current MFRPS State Implementation Status February 3, :15 – 9:45 am Timothy Weigner Staff Director U.S. FDA Office of Regulatory Affairs, Office.
Mammography Regulations and Standards in the U.S.: The Basics of the Mammography Quality Standards Act Helen J. Barr, MD Director, Division of Mammography.
Project P.R.O. What is it? Project 37 becomes Project PRO PRO P rofessional R ecognition O btainment The Project Goal is to create a professional certification.
Slide 1 POA Seminar 02 March 2016 Personnel Competence Including Certifying Staff and Release to Service Andy Swift / Michael Greer.
DEVELOPMENT OF HUMAN RESOURCES AT THE STATE AUDIT OFFICE OF THE REPUBLIC OF LATVIA State Audit Office of the Republic of Latvia Skanstes 13, Riga LV-1013.
8 Nobermer, 2010 Sungsoo Chun, MPH, PhD, Easton Reid, PhD, Mi-Kyung Kim Korean Institute on Alcohol Problems School of Health and Welfare, Sahmyook University,
Import Safety Phase 2 Workgroup 1.
Screeners and the Screener Organisation
American Society for Quality Region 5 Quality Conference
Introduction to Agribusiness Management
Career Banding Program for North Carolina State Government Employees
Recruitment & Selection Process For Talent Acquisition
Certified Information Technology Professional (CITP) Credential
Presentation transcript:

FDA’s Pharmaceutical Inspectorate Robert Coleman National Expert Drug Investigator Food and Drug Administration

Certification

Background Certification begun in 1994 To create consistent inspectional activities nationally through a uniformly managed training & audit process for our investigators. Will proceed as long as adequate funding and support exists.

Purpose Provide training to develop & maintain a qualified & effective staff of investigators. Provide a structured mechanism for investigators to obtain, maintain & consistently apply the required competencies Objective: Assure our Investigators continue to have the skills & knowledge necessary to do their jobs.

Players Human Resource Committee Division of Human Resource Development Course Advisory Committee(s) Certification Board(s) Performance Auditors Certification Candidates District Management Office of the Director of Regional Operations Division of Field Investigations

Program Areas with Certification Medical Devices BloodSeafoodDrugs

Drug Certification Level I Level II Level III

Level I Mandatory For all new hire investigators Training completed in the first 12- months. Demonstration of competency via a successful performance audit results in Level I Certification.

Level I Training Web based training courses and OJT experience Classroom training courses –Basic Food and Drug Law –Evidence Development –Investigative Interviewing –Quality Auditing

Level I Audit Criteria First line supervisor looks for: –General Investigational Practices –Evidence Recognize, Collect and Identify Appropriate Evidence to Support Findings –Verbal Communication –Written Communication –Professionalism

Level II Drug Certification Not mandatory Candidate must –Spend at least 25% of time in drug program –Submit packet to Level II Drug Certification Board –Pass performance audit –The Performance Auditor is a Board Approved FDA employee who completed their Level II Certification –Be recertified every 3 years (18 CEU hours)

Level II Drug Investigator Certification Prerequisites Must meet Level I criteria Required training courses –Drug Manufacturing & Quality Control Training Course –Pre-Approval Inspections Training Course –Industrial Sterilization of Drugs & Devices Training Course –Computer Systems Validation Training Course –Active Pharmaceutical Ingredient Manufacturing Training

Level II Certification Board National Expert Experienced Field Investigator Expert from CDER Expert from CVM Field Manager DHRD Specialist

Level II Audit Criteria Compliance assessment Evidence Verbal Communication Written Communication Professionalism

Level III Drug Certification AKA “Pharmaceutical Inspectorate” Not mandatory Planning for 50 members by FY07

Who is eligible for the PI? FDA employees with at least 3 years of experience in inspecting drug firms. –ORA Field Investigators –CDER/CVM personnel –Investigative analysts Certified at Level II –Must pass a six system audit Endorsed by District/Office management Selected/nominated by Level III Certification Board

How do they join? Submit their name to their supervisor for consideration. Initial nomination will have concurrence from their District management. Submit a certification packet to the Level III Drug Investigator Certification Board for review and selection. The Certification Board will screen the applicant.

Level III Drug Certification Board 2 Field Investigators (National Experts) operating at Level III 2 Experts from the CDER 2 Experts from the CVM 1 DFI Program Expert 1 ORA Field Manager from the appropriate Field Committee 1 Representative from DHRD

Who are the candidates? FDA personnel (mainly Investigators) with specialized experience & specific training in evaluating pharmaceutical manufacturing. Report directly to ORA District Office management for assignments. Spend about 80% of their time conducting drug inspections (domestic & foreign) and related activities.

Expected Competencies for PI Regulating Pharmaceutical Quality and the Relationship to FDA’s Mission Risk Management Advanced Quality Systems Pharmaceutical Science Current Regulatory Programs and Procedures TechnologyInvestigational

Selection Criteria for the PI Candidate demonstrates: –Willingness to share his/her knowledge with colleagues –Initiative to go beyond the “expected” or “required” –Innate ability to separate important issues from unimportant issues –Currency of knowledge –Desire to excel

Selection Criteria for the PI Candidates will: –Primarily focus on conducting pharmaceutical inspections –Successfully meet all Level I and Level II requirements –Recognize when additional training is needed –Be a recognized resource on advanced technology or inspectional techniques –Demonstrate effective verbal and written communication skills

Admission to the PI To become a PI member the candidate must: –Have their packet successfully reviewed –Pass the screening –Pass the training –Participate in Center details –Pass final evaluation

What training will be provided? First course completed in 2005 Second course scheduled in 2006 –Still under development

Some Course Agenda Items Quality Systems & Tools Risk Assessment & Management Critical Thinking Quality by Design Design of Experiments ICH Guidances Process Capability Technology Transfer CAPAPAT

PI Course Advisory Group ORA, CDER training manager & trainers ORA/DFI representatives ORA Field investigator ORA Field Manager CDER, CVM representatives Others (on a course by course basis)

PI Expectations Seek additional activities to further their expertise. Develop & implement formal training programs for FDA, industry, and state/local officials. Develop/evaluate programs, policies, or procedures in their area of expertise. Auditors for the Level II or III Drug Certification programs. Participate in professional activities that maintain, broaden, or enhance their knowledge.

HOW TO REACH ME Robert C. Coleman US FDA 60 Eighth Street, N.E. Atlanta, Georgia USA Tel: FAX: